1. Home
  2. BHVN vs STOK Comparison

BHVN vs STOK Comparison

Compare BHVN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BHVN

Biohaven Ltd.

HOLD

Current Price

$15.44

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$29.01

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHVN
STOK
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
BHVN
STOK
Price
$15.44
$29.01
Analyst Decision
Buy
Strong Buy
Analyst Count
14
10
Target Price
$29.08
$39.20
AVG Volume (30 Days)
3.6M
1.0M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
26.08
92.73
EPS
N/A
N/A
Revenue
N/A
$184,420,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$77.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
404.50
52 Week Low
$7.48
$12.25
52 Week High
$18.57
$40.22

Technical Indicators

Market Signals
Indicator
BHVN
STOK
Relative Strength Index (RSI) 57.56 38.38
Support Level $14.44 $28.22
Resistance Level $17.01 $33.51
Average True Range (ATR) 1.01 1.56
MACD -0.28 -0.38
Stochastic Oscillator 49.72 12.29

Price Performance

Historical Comparison
BHVN
STOK

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: